Aquestive Therapeutics, Inc. (AQST): Price and Financial Metrics
GET POWR RATINGS... FREE!
AQST POWR Grades
- AQST scores best on the Value dimension, with a Value rank ahead of 60.09% of US stocks.
- AQST's strongest trending metric is Stability; it's been moving up over the last 31 weeks.
- AQST's current lowest rank is in the Stability metric (where it is better than 9.36% of US stocks).
AQST Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for AQST is -0.93 -- better than merely 4.42% of US stocks.
- Aquestive Therapeutics Inc's stock had its IPO on July 25, 2018, making it an older stock than only 7.67% of US equities in our set.
- Equity multiplier, or assets relative to shareholders' equity, comes in at -1.51 for Aquestive Therapeutics Inc; that's greater than it is for only 5.03% of US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to Aquestive Therapeutics Inc are PRTK, QMCO, OMER, TXMD, and AMRS.
- Visit AQST's SEC page to see the company's official filings. To visit the company's web site, go to www.aquestive.com.
AQST Price Target
For more insight on analysts targets of AQST, see our AQST price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $14.67 | Average Broker Recommendation | 1.42 (Moderate Buy) |
AQST Stock Price Chart Interactive Chart >
AQST Price/Volume Stats
| Current price | $4.02 | 52-week high | $9.47 |
| Prev. close | $4.06 | 52-week low | $3.17 |
| Day low | $3.94 | Volume | 420,889 |
| Day high | $4.07 | Avg. volume | 790,119 |
| 50-day MA | $3.87 | Dividend yield | N/A |
| 200-day MA | $5.40 | Market Cap | 147.10M |
Aquestive Therapeutics, Inc. (AQST) Company Bio
Aquestive Therapeutics, Inc. operates as a specialty pharmaceutical company that specializes in the drug delivery technology. The company offers PharmFilm, a drug delivery platform/pharmaceutical dosage form that delivers existing prescription products directly to the bloodstream. It develops, manufactures, and commercializes pharmaceutical films, individual film doses, and finished products for patients, physicians, and caregivers. Aquestive Therapeutics, Inc. was formerly known as MonoSol Rx Inc. and changed its name to Aquestive Therapeutics, Inc. in November 2017. The company was founded in 2000 and is based in Warren, New Jersey.
Latest AQST News From Around the Web
Below are the latest news stories about Aquestive Therapeutics Inc that investors may wish to consider to help them evaluate AQST as an investment opportunity.
Aquestive Therapeutics to Participate in JMP Securities and BMO Capital Market Investor ConferencesAquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients unmet needs and solve therapeutic problems, announced today that the management team will participate in two upcoming investor conferences in June. |
NASDAQ:AQST Long Term Investor Notice: Investigation over Possible Wrongdoing at Aquestive Therapeutics, Inc.An investigation on behalf of current long term investors in Aquestive Therapeutics, Inc. (NASDAQ:AQST) shares over possible breaches of fiduciary duty by certain officers and directors was announced. San Diego, CA -- ( SBWIRE ) -- 05/24/2021 -- Certain directors of Aquestive Therapeutics, Inc. are under investigation over possible breaches of fiduciary duties. Investors who are current long term investors in Aquestive Therapeutics, Inc. (NASDAQ: AQST) shares, have certain options and should contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554. The investigation by a law firm for investors in NASDAQ: AQST stocks follows a lawsuit filed against Aquestive Therapeutics, Inc. over alleged securities laws violations. The investigation on behalf of... |
The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics DebutsHere's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 13) Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) Novo Nordisk A/S (NYSE: NVO ) Vaccitech plc (NASDAQ: VACC ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 13) 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT ) ADC Therapeutics SA (NYSE: ADCT ) Accelerate Diagnostics, Inc. (NASDAQ: AXDX ) Achilles Therapeutics plc (NASDAQ: ACHL ) Akouos, Inc. (NASDAQ: AKUS ) (announced its first-quarter results) Applied Genetic Technologies Corporation (NASDAQ: AGTC ) Aprea Therapeutics, Inc. (NASDAQ: APRE ) Aquestive Therapeutics, Inc. (NASDAQ: AQST ) Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT ) Atea Pharmaceuticals, Inc. (NASDAQ: AVIR ) Atreca, ... |
The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For HeronHere's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 11) HOOKIPA Pharma Inc. (NASDAQ: HOOK ) Novo Nordisk A/S (NYSE: NVO ) West Pharmaceutical Services, Inc. (NYSE: WST ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 11) 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT ) 4D pharma plc (NASDAQ: LBPS ) Acutus Medical, Inc. (NASDAQ: AFIB ) Adagene Inc. (NASDAQ: ADAG ) Adaptive Biotechnologies Corporation (NASDAQ: ADPT ) ADC Therapeutics SA (NYSE: ADCT ) Agile Therapeutics, Inc. (NASDAQ: AGRX ) Akouos, Inc. (NASDAQ: AKUS ) (reacted to presentation of non-clinical data on gene therapy candidates at the American Society of Gene and Cell Therapy meeting) Akoya Biosciences, Inc. (NASDAQ: AKYA ) Ap... |
The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On EarningsHere's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 10) AbbVie Inc. (NYSE: ABBV ) - Its Allergan subsidiary announced a deal to buy Soliton, Inc. (NASDAQ: SOLY ) Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) Novo Nordisk A/S (NYSE: NVO ) Quest Diagnostics Incorporated (NYSE: DGX ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 10) 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT ) 4D pharma plc (NASDAQ: LBPS ) Accelerate Diagnostics, Inc. (NASDAQ: AXDX ) Acutus Medical, Inc. (NASDAQ: AFIB ) Adagene Inc. (NASDAQ: ADAG ) Adaptive Biotechnologies Corporation (NASDAQ: ADPT ) Agile Therapeutics, Inc. (NASDAQ: AGRX ) Akoya Biosciences, Inc. (NASDAQ: AKYA ) Aquestive Therapeutics, Inc. (NASDAQ: A... |
AQST Price Returns
| 1-mo | 17.20% |
| 3-mo | -22.24% |
| 6-mo | -41.91% |
| 1-year | -23.14% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -24.86% |
| 2020 | -8.08% |
| 2019 | -7.62% |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Continue Researching AQST
Want to see what other sources are saying about Aquestive Therapeutics Inc's financials and stock price? Try the links below:Aquestive Therapeutics Inc (AQST) Stock Price | Nasdaq
Aquestive Therapeutics Inc (AQST) Stock Quote, History and News - Yahoo Finance
Aquestive Therapeutics Inc (AQST) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...